bioMérieux

Regulatory Filings • Feb 1, 2023

MAESTRIA™, a new generation microbiology middleware developed by bioMérieux to optimize laboratory workflow and improve patient care

Marcy-l'Étoile, France – February 1st, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, launches MAESTRIATM. This new generation middleware for the microbiology laboratory aims at providing a central software tool for the workflow management of all routine activities.

With automation and digitalization of diagnostic solutions, clinical microbiology laboratories need to handle more and more medical data along the healthcare pathway. They require specific software solutions to help manage the growing needs for workflow optimization, biological expertise and data management. Managing workload in a timely manner and ensuring the quality of the testing workflow are everyday challenges in order to assist the various health professionals in their decision-making process for optimizing patient care.

The central tool for the management of routine activities in microbiology

MAESTRIA™ is the new generation microbiology middleware from bioMérieux, managing specimens from the moment they are logged into the laboratory workflow until the final testing results are available. This software with a state-of-the-art graphical user interface covers various workflow steps including staining results or manual input of offline Antimicrobial Susceptibility Testing (AST) results, in addition to all connectable instruments. MAESTRIA™ also allows to define customer-specific AST interpretation rules, merging results from multiple methods - either online or manual - to consolidate one final antibiogram. Thanks to the additional CLARION™ Lab Analytics module, a data visualization feature, MAESTRIA™ transforms data into real-time, easy-to-access and actionable insights.

A solution created by microbiologists for microbiologists

MAESTRIA™ was designed and developed to meet users' expectations, collected through years of experience in the field of microbiology middleware, and iteratively approved by a number of clinical microbiology laboratories worldwide.

Already available for a number of pilot sites, MAESTRIA™ is being progressively launched globally through 2023. Customer feedback helps demonstrate the value of MAESTRIATM in the lab routine and also provides broader workflow coverage and new features through continuous improvement.

Mark Miller, Executive Vice President, Chief Medical Officer, noted: "With MAESTRIA™, our goal is to provide the much-needed software tools for clinical laboratories that will help make the most of testing workflows, but also to move towards easier, quicker and more reliable surveillance and rapidly easily accessible data to help clinicians to make vital patient management decisions. Data from the laboratory is crucial for understanding the local epidemiology and resistance patterns for optimal Antimicrobial Stewardship, thus benefiting interventions to better combat Antimicrobial Resistance and improve patient outcomes."

Pierre Boulud, Chief Operating Officer, Clinical Operations, declared: "MAESTRIA™ is a very innovative and high value-added software solution, leveraging bioMérieux recognized expertise as a leading IVD company. bioMérieux further reinforces its positioning as a leader in Infectious Diseases Diagnostics, with cutting edge technology, not only for testing, but also for the management of the generated data. This serves the needs of our customers, for the benefit of patients."

ABOUT BIOMÉRIEUX VISION SUITE

BIOMÉRIEUX VISION SUITE turns laboratory and hospital data into insightful and actionable information to support diagnostic and clinical decisions at all stages, from individual patient care to public health surveillance, to better support Antimicrobial Stewardship. By providing a comprehensive suite of software products and services that collect, analyze and merge various sources of data, BIOMÉRIEUX VISION SUITE empowers our users to make the right decisions at the right time. Learn more

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.4 billion, with over 90% of international sales (outside of France).

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agrifood, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: www.biomerieux.com.

CONTACTS

Investor Relations bioMérieux Franck Admant Tel.: +33 (0)4 78 87 20 00 investor.relations@biomerieux.com

Media Relations

bioMérieux Image Sept media@biomerieux.com lheilbronn@image7.fr cdoligez@image7.fr

Romain Duchez Laurence Heilbronn Claire Doligez Tel.: +33 (0)4 78 87 21 99 Tel.: +33 (0)1 53 70 74 64 Tel.: +33 (0)1 53 70 74 48